EA201790973A1 - A-антагонист в низкой дозировке для лечения adhd и болезни паркинсона - Google Patents

A-антагонист в низкой дозировке для лечения adhd и болезни паркинсона

Info

Publication number
EA201790973A1
EA201790973A1 EA201790973A EA201790973A EA201790973A1 EA 201790973 A1 EA201790973 A1 EA 201790973A1 EA 201790973 A EA201790973 A EA 201790973A EA 201790973 A EA201790973 A EA 201790973A EA 201790973 A1 EA201790973 A1 EA 201790973A1
Authority
EA
Eurasian Patent Office
Prior art keywords
parkinson
disease
antagonist
low dosage
adhd treatment
Prior art date
Application number
EA201790973A
Other languages
English (en)
Inventor
Лоун Фрайделанд Ларсен
Йохан Эйрберг
Натали Брейс
Гамини Чандрасена
Original Assignee
Х. Лундбекк А/С
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Х. Лундбекк А/С filed Critical Х. Лундбекк А/С
Publication of EA201790973A1 publication Critical patent/EA201790973A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4436—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates

Abstract

Изобретение относится к конкретным дозировкам антагониста A-рецепторов для применения в качестве лекарственного препарата, и он особенно применим для лечения болезни Паркинсона и синдрома дефицита внимания/гиперактивности.
EA201790973A 2014-12-03 2015-12-01 A-антагонист в низкой дозировке для лечения adhd и болезни паркинсона EA201790973A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DKPA201400704 2014-12-03
PCT/EP2015/078181 WO2016087429A1 (en) 2014-12-03 2015-12-01 Low dosage a2a antagonist for the treatment of adhd and parkinsons

Publications (1)

Publication Number Publication Date
EA201790973A1 true EA201790973A1 (ru) 2017-10-31

Family

ID=58731664

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201790973A EA201790973A1 (ru) 2014-12-03 2015-12-01 A-антагонист в низкой дозировке для лечения adhd и болезни паркинсона

Country Status (25)

Country Link
US (2) US20160158211A1 (ru)
EP (1) EP3226863A1 (ru)
JP (1) JP2017536400A (ru)
KR (1) KR20170090430A (ru)
CN (1) CN106999480A (ru)
AU (1) AU2015357197A1 (ru)
BR (1) BR112017011777A2 (ru)
CA (1) CA2966582A1 (ru)
CL (1) CL2017001407A1 (ru)
CO (1) CO2017004785A2 (ru)
CR (1) CR20170221A (ru)
DO (1) DOP2017000121A (ru)
EA (1) EA201790973A1 (ru)
EC (1) ECSP17030050A (ru)
IL (1) IL252355A0 (ru)
MA (1) MA41090A (ru)
MX (1) MX2017007027A (ru)
NI (1) NI201700066A (ru)
PE (1) PE20170926A1 (ru)
PH (1) PH12017500923A1 (ru)
SG (1) SG11201704370XA (ru)
SV (1) SV2017005441A (ru)
TN (1) TN2017000174A1 (ru)
TW (1) TW201632186A (ru)
WO (1) WO2016087429A1 (ru)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI829857B (zh) 2019-01-29 2024-01-21 美商英塞特公司 作為a2a / a2b抑制劑之吡唑并吡啶及三唑并吡啶
CN114917350B (zh) * 2022-06-21 2023-06-13 重庆医科大学附属第二医院 Cftr增强剂在注意缺陷与多动障碍中的应用及产品

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3002283B1 (en) * 2003-12-26 2017-06-14 Kyowa Hakko Kirin Co., Ltd. Thiazole derivatives
EA023267B1 (ru) * 2008-07-23 2016-05-31 Киова Хакко Кирин Ко., Лтд. Способ для лечения и/или предотвращения мигрени
TWI548411B (zh) * 2009-04-28 2016-09-11 Kyowa Hakko Kirin Co Ltd Exercise disorder treatment
UA110097C2 (uk) * 2009-09-02 2015-11-25 Терапевтичний агент для лікування розладів настрою
UA113383C2 (xx) * 2009-09-02 2017-01-25 Терапевтичний агент для лікування тривожних розладів

Also Published As

Publication number Publication date
PE20170926A1 (es) 2017-07-13
CL2017001407A1 (es) 2018-01-05
SG11201704370XA (en) 2017-06-29
CO2017004785A2 (es) 2017-08-31
ECSP17030050A (es) 2017-08-31
MX2017007027A (es) 2017-08-24
CN106999480A (zh) 2017-08-01
BR112017011777A2 (pt) 2018-02-20
TW201632186A (zh) 2016-09-16
CA2966582A1 (en) 2016-06-09
KR20170090430A (ko) 2017-08-07
SV2017005441A (es) 2017-08-25
TN2017000174A1 (en) 2018-10-19
NI201700066A (es) 2018-01-04
WO2016087429A1 (en) 2016-06-09
IL252355A0 (en) 2017-07-31
AU2015357197A1 (en) 2017-05-25
US20180125835A1 (en) 2018-05-10
EP3226863A1 (en) 2017-10-11
CR20170221A (es) 2017-10-05
PH12017500923A1 (en) 2017-11-20
MA41090A (fr) 2017-10-10
JP2017536400A (ja) 2017-12-07
DOP2017000121A (es) 2017-07-15
US20160158211A1 (en) 2016-06-09

Similar Documents

Publication Publication Date Title
JOP20200192A1 (ar) أجسام مضادة لـ tigit
EA201790273A1 (ru) Флагеллиновые композиции и их применение
EA201691582A1 (ru) Новые фармацевтические препараты
EA201991484A1 (ru) Лекарственные формы энзалутамида
UA116648C2 (uk) Фумарати як проліки та їх застосування при лікуванні різних захворювань
EA201591616A1 (ru) Трифторметил-замещенные аннелированные пиримидины и их применение
TR201901886T4 (tr) DNA-PK inhibitörleri.
EA201790785A1 (ru) Производные тетрагидроизохинолина
EA201691481A1 (ru) ИНГИБИТОРЫ C5a ДЛЯ ЛЕЧЕНИЯ ВИРУСНОЙ ПНЕВМОНИИ
EA201692109A1 (ru) Варианты антител к фактору d и их применение
EA201692313A1 (ru) Производные индолизина в качестве ингибиторов фосфоинозитид-3-киназ
CL2015002897A1 (es) Inhibidores de bace1
EA201590359A1 (ru) Лечение ревматоидного артрита
EA201790442A1 (ru) Трициклические азотсодержащие соединения для лечения инфекции, вызываемой neisseria gonorrhoeae
EA201790312A1 (ru) Комбинации лекарственных средств для лечения множественной миеломы
EA201690039A1 (ru) Ингибиторы rorc2 и способы их применения
EA201791174A1 (ru) Антимикотическое соединение
EA201691108A1 (ru) Хиназолин-thf-амины в качестве ингибиторов pde1
EA201791819A1 (ru) Комбинированная терапия с применением конъюгата антитела против cd19 с лекарственным средством и винкристина
EA201790973A1 (ru) A-антагонист в низкой дозировке для лечения adhd и болезни паркинсона
EA201790609A1 (ru) Макроциклические ингибиторы rip2-киназы
EA201691335A1 (ru) Гексагидрофуропирролы в качестве ингибиторов pde1
TR201903234T4 (tr) Parkinson hastalığının tedavisinde kullanılmaya yönelik dopamin içeren farmasötik çözelti.
EA201790020A1 (ru) Соединения, фармацевтические композиции и их применение при лечении нейродегенеративных заболеваний
EA201501177A1 (ru) Фармацевтические композиции